docetaxel + fluorouracil

Docetaxel + fluorouracil is a combination chemotherapy regimen consisting of two cytotoxic agents used primarily in the treatment of advanced solid tumors. Docetaxel is a taxane that promotes microtubule assembly and inhibits their disassembly, leading to cell cycle arrest and apoptosis. Fluorouracil (5-FU) is an antimetabolite that interferes with DNA synthesis by inhibiting thymidylate synthase. The combination has demonstrated synergistic activity in preclinical models and clinical studies, particularly for advanced gastric cancer, head and neck cancers, metastatic breast cancer, and other solid tumors. This regimen may be administered as part of multi-drug protocols or as a doublet therapy in various investigational settings[2][5].

Brand names

Taxotere + Adrucil

Other names

docetaxel and 5-fluorouracildocetaxel and 5-FUTaxotere plus 5-FU